SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $342 | -8.3% | 12,416 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $373 | -17.1% | 12,416 | 0.0% | 0.00% | -33.3% |
| Q1 2023 | $450 | +1.6% | 12,416 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $443 | -99.9% | 12,416 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $420,000 | +17.0% | 12,416 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $359,000 | -10.5% | 12,416 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $401,000 | -17.3% | 12,416 | -25.3% | 0.00% | 0.0% |
| Q4 2021 | $485,000 | +9.5% | 16,616 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $443,000 | -13.5% | 16,616 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $512,000 | +95.4% | 16,616 | +65.9% | 0.00% | +200.0% |
| Q1 2021 | $262,000 | +4.0% | 10,016 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $252,000 | +20.6% | 10,016 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $209,000 | -56.1% | 10,016 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $476,000 | – | 20,032 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |